Last reviewed · How we verify
Repertaxin
Repertaxin is a Small molecule drug developed by Dompé Farmaceutici S.p.A. It is currently in Phase 2 development.
Repertaxin is a small molecule that modulates the interleukin-8 receptor A, classified as a MODULATOR. It is being studied in clinical trials for various conditions, including ischemia-reperfusion injury, lung transplantation, acute respiratory distress syndrome, fatigue, and locally advanced or metastatic breast cancer.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Repertaxin |
|---|---|
| Sponsor | Dompé Farmaceutici S.p.A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (PHASE3)
- Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) (PHASE2)
- Add-on Reparixin in Adult Patients With ARDS (PHASE2)
- Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation (PHASE2)
- Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation (PHASE2)
- Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia. (PHASE3)
- To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer (PHASE2)
- Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Repertaxin CI brief — competitive landscape report
- Repertaxin updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI
Frequently asked questions about Repertaxin
What is Repertaxin?
Who makes Repertaxin?
What development phase is Repertaxin in?
Related
- Manufacturer: Dompé Farmaceutici S.p.A — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing